Alzheimer’s Matters, the official blog of the ADDF, features insights, perspectives and commentary on current topics of interest in Alzheimer’s disease and related drug discovery.
Executive Director Howard Fillit, MD, discusses epigenetic treatments, one of the newest and most promising areas of our portfolio.
Ernest Scheyder, a returning member of the ADDF’s TCS NYC Marathon team, shares why he is running for Alzheimer’s research and how you can help him and the rest of our dedicated runners.
For the first time, a treatment has reduced amyloid beta plaques in the brains of patients with Alzheimer’s disease.
Karen Mason reflects on her late husband, Tommy Mason, whom she describes as "larger than life," a trait that remained even as he endured the effects of Alzheimer’s.
With support from the ADDF, Carmela Abraham, PhD, recently founded a biotech company to accelerate the development of a new class of drugs to combat Alzheimer’s disease
Grantee Dr. Frank Longo's promising new drug to treat Alzheimer's is on the cover of Time magazine
Executive Director Howard Fillit, MD, looks back at 2015—our most successful year ever—and thanks the supporters and scientists who made it possible
Planning holidays and other celebrations is challenging when a loved one has dementia. Adam Rowe shares his experience with planning his parents' 50th anniversary while accommodating limitations caused by his mother's frontotemporal dementia.
For #GivingTuesday 2015, we invite you learn more about our critical work to conquer Alzheimer's.
Allison Johnson, a member of or first official TCS New York City Marathon team, shares why she's running for Alzheimer's